

	Early-onset n = 143	Late-onset n = 1141	P-value
Sex, n (male/female)	65/78	835/306	<0.001
ECOG PS 0-1, n (%)	136 (94)	1050 (95)	0.24
Family history of cancer n (%)	104 (74)	757 (68)	0.23
Smoking, n (%)	34 (24)	661 (60)	<0.001
Alcohol, n (%)	9 (7.0)	190 (18)	0.0013
Primary site, n (EGJ/stomach)	15/128	102/1039	0.54
Main histological type, n (%)			<0.001
Diffuse	66 (46)	286 (25)	
Intestinal	75 (52)	850 (74)	
Special	2 (1.4)	5 (0.44)	
HER2 score, n (0/1+/2+/3+)	83/21/8/19	546/179/136/133	0.073
Genomic profiling test			0.43
F1CDx	110 (77)	866 (76)	
NOP	18 (13)	111 (9.7)	
F1L	15 (10)	146 (13)	
Guardant 360	0	10 (0.88)	
TOP	0	8 (0.70)	
Tissue sampling area, n (primary/metastatic)	95/33	857/128	0.0003
Types of first-line treatment regimens, n (%)			
Fluoropyrimidine+platinum	28 (20)	200 (17.5)	0.0025
Nivo+Fluoropyrimidine+platinum	19 (13)	50 (4.4)	
Tmab+Fluoropyrimidine+platinum	6 (4.2)	50 (4.4)	
Fluoropyrimidine monotherapy	5 (3.5)	60 (5.3)	
Nivo monotherapy	1 (0.7)	7 (0.6)	
Others or unknown	84 (59)	768 (67)	

Table 1. Clinical characteristics

Regarding the types of first-line treatment regimens, fluoropyrimidine include S-1, capecitabine, and 5-FU, while platinum agents include oxaliplatin or cisplatin.

ECOG-PS, Eastern Cooperative Oncology Group performance status; EGJ, esophagogastric junction; HER2, human epidermal growth factor receptor 2; F1CDx, FoundationOne CDx; NOP, OncoGuide™ NCC Oncopanel System; F1L, FoundationOne Liquid CDx; Guardant 360, Guardant 360 CDx; TOP, GenMine TOP, Tmab; trastuzumab, Nivo; nivolumab.